INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Core Insights - INmune Bio, Inc. has published a study demonstrating that XPro1595 promotes remyelination in an animal model of demyelinating disease, with implications for various CNS diseases including Alzheimer's [1][2] - The study identifies soluble TNF as a critical cytokine checkpoint that can convert microglia from a reparative to a damaging state, suggesting that blocking soluble TNF may be a promising strategy for treating demyelinating diseases [2] - INmune Bio anticipates reporting top-line cognitive results from an ongoing Phase II trial in early Alzheimer's patients in the first half of 2025 [2] Company Overview - INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases [4] - The company has two product platforms in clinical trials: the Dominant-Negative Tumor Necrosis Factor (DNTNF) platform and the Natural Killer Cell Priming Platform [4] - XPro1595 is the first product from the DNTNF platform, currently in trials for Mild Alzheimer's disease, with plans to explore additional indications such as treatment-resistant depression and oncology [4] Demyelination in Alzheimer's Disease - Research indicates that demyelination occurs in brain regions critical for cognition in Alzheimer's patients, often associated with amyloid-beta plaques [3] - Myelin loss may precede or accompany classic pathological changes in Alzheimer's, with alterations in myelin density detectable before typical symptoms arise [3] - Mechanisms of myelin damage in Alzheimer's involve oligodendrocyte dysfunction, contributing to a feedback loop that exacerbates both myelin loss and neurodegeneration [3]